The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV‑01, which was developed using a proprietary TLI vaccine technology platform, is poised to move forward in development up to and including Phase 1 clinical evaluation — enabled by a major contract awarded to a collaboration  consortium of Vitalex and Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The contract from the National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) is valued at up to US $40 million. It will support the development of VXV-01 from manufacturing and non-clinical studies through two Phase 1 clinical trials. This contract represents a significant milestone for The Lundquist Institute’s vaccine research program. 

Rifampicin, the main treatment for TB, is losing ground against drug-resistant bacteria and dormant infections, underscoring the need for smarter combination strategies. Pairing rifampicin with the compound AAP-SO₂ turns a common resistance mutation into a vulnerability, dramatically boosting the potency of both drugs in knocking out dormant infections hiding in cell clusters. The findings suggest that TB treatment could take a more precision medicine approach, pairing rifampicin with a second transcription inhibitor to exploit vulnerabilities linked to drug resistance, and potentially enable more such dual-drug therapies in the future.

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance demonstrated in studies in mice that could lay the groundwork for safer, more precise treatments for cancer and other diseases. The system, called the cell-selective modRNA translation system (cSMRTS), is an engineered form of mRNA designed to activate in specific cell populations. The findings were reported in the November 15 online issue of Molecular Therapy, a Cell Press journal.

In an Annenberg Public Policy Center white paper, biostatistician Jeffrey Morris of the University of Pennsylvania's Perelman School of Medicine analyzes the U.S. vaccine safety monitoring system and suggests how its components, including VAERS, can be improved.